Humanized or fully human monoclonal antibodies specially designed to break cancer immune tolerance by restoring T cell recognition against tumor cells, ICIs dampen the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1)/ligand (PD-L1) pathways. Here, PDCD1 is linked to cancer.